OncoC4's Cesalatamig: Promising Results in NSCLC Trials
Hope in Persistence: Cesalatamig in the Spotlight Swinging through the medical landscape like a seasoned fighter, OncoC4's recent revelations at the SITC 2026 give investors and doctors a reason to pay close attention. We're sizing up their investigational drug, cesalatamig, which flaunts a solid objective response rate of 33% among non-small cell lung cancer (NSCLC)...
Continue Reading
